Introduction
The thyrotropin-releasing hormone (TRH) analogue, 
Nƒ¿-[{(S)-4-oxo-2-azetidinyl}-carbony1]-L-histidyl-L-

Materials and Methods Surgical procedures
Male Sprague-Dawley rats weighing 260-330 g were anaesthetized with ketamine HC1 (10 mg/kg i.p.), supplemented during surgery with halothane (0.5-4 % when appropriate). The surgical and recording procedures were as previously described (10, (13) (14) (15) (16) . A small lightemitting diode was fixed to the mandible and the animal was placed in a stereotactic frame so that the head was kept in constant relation to a light-sensitive transducer which detected the vertical and horizontal movements of the diode. Bipolar electrodes were placed into the masseter and digastric muscles to record electromyographic (EMG) activity. The spinal cord was transected at the Cl level to confine drug-induced movements to the head region. The jaw movements were recorded on a polygraph for later quantification and were automatically counted with a spike trigger. The sessions lasted 240 min. Guide cannulae (0.5 mm o.d., 0.3 mm i.d. 6.0 mm length) were implanted bilaterally into the brain according to previously described procedures (10, 11, 13) . The coordinates based on the atlas of Paxinos and Watson (17) were: for the shell, anterior = 10.6 mm, vertical = 2.0 mm, lateral = 0.5 mm; for the core, anterior = 10.6 mm, vertical = 3.0 mm, lateral = 1.2 mm (Fig. 1) . The cannulae directed at the shell were angled 21 degrees from the mid-sagittal plane and those directed at the core were angled 18 degrees from this plane to avoid the ventricular system. The injection of 0.2 1,1,1 per side was delivered over a 20 s period, and the needle was left in position for an additional 20 s period after completion of the injection. Damage to the target site was minimized by implanting the tips of the guide cannulae 1.2 mm (for the core) or 2.0 mm (for the shell) above the desired injection site. Wire stylets were placed in the guide cannulae to prevent occlusion. After surgery, the animals were maintained under anaesthesia by continuous infusion of ketamine (10 mg/h i.v.). Lignocaine HC1 (2 %) gel was applied to all incisions and the rectal temperature was maintained at 37°C with a thermostatically controlled heating pad. Monitored concentrations of 02 and CO2 expired during the experiment were 19-21 % and 2.0-2.5 %, respectively. The number of jaw openings greater than 1 mm (measured from the diode displacement) was counted in consecutive 5 min periods for 240 min according to our previously described paradigms (16, 18) . Jaw movements and EMG activity were also recorded on a polygraph for further analysis of the pattern of jaw movements (16, 18) . All experiments were performed according to institutional and national guidelines for animal experimentation.
Drugs
The animals (n = 6-7 per experiment) received bilateral injections of the TRH analogue YM-14673 (0.1 jig or 1.0 significantly differ from that in vehicle treated animals. In contrast, this mixture was highly effective when injected into the shell (p < 0.001, two-way ANOVA). These time-dependent effects are shown in Fig. 2B . This figure clearly illustrates that the effect started almost immediately after the injection, reached its peak around 40 min and vanished at about 120 min after injection.
Effects of YM-14673 injection into the shell and the core of the nucleus accumbens on jaw Digastric and masseter muscles showed continuous activity throughout the period of maximum drug effect. Frequent tongue protrusions occurred during the large amplitude jaw openings. This pattern was similar to that previously described (16, 18) . Discussion As mentioned in the Introduction, there exists increasing evidence showing that the shell and the core of the nucleus accumbens differ in terms of anatomy (2) (3) (4) (5) (6) (7) (8) and pharmacology (9) (10) (11) (12) . The outcome of the present study confirms the earlier reported findings that the shell, but not the core, of the nucleus accumbens is involved in the control of oral movements, especially jaw movements induced by co-stimulation of dopamine Di and D2 receptors (10) (11) (12) : the combined administration of SKF 82958 and quinpirole was only effective when injected into the shell, but not the core, of the nucleus. The finding that the shell of the nucleus accumbens is especially involved in oral behaviour is understandable in view of the fact that the shell projects to a part of the ventral pallidum (20) that is known to be involved in oral behaviour (21) .
It has also been shown that the nucleus accumbens play a role in jaw movements elicited by YM-14673 (1). Since the response to YM-14673 was attenuated by the dopamine D1/D2 receptor antagonist cis-(Z)-flupentixol (1), it is suggested that YM-14673 directly or indirectly enhanced the dopamine activity at the level of dopamine D1/D2 receptors.
These findings give rise to the hypothesis that the shell of the nucleus accumbens plays a role in the display of the YM-14673-induced jaw movements that differs from that played in the core. The outcome of the present study shows a lack of significant difference between the effects of shell and the core; thus, YM-14673 injected into the shell and the core of the nucleus accumbens similarly elicited repetitive jaw movements in a dose-related manner. The absence of any significant difference between the shell and the core in this respect give rise to two alternative explanations. First, both treatments elicited identical effects, because YM-14673 diffused from the shell to the core, and/or vice versa. In that case, it is still possible that the role of the shell in YM-14673-induced jaw movements differs from that of the core. Second, the shell shares its role with that of the core. Further research is required to solve this problem.
This study reports at least two findings indicating that YM-14673 has pharmacologically distinct effects from the D1/D2 dopamine-receptor agonists. First, the pattern of jaw movements induced by YM-14673 is not identical to that elicited by stimulation of dopamine Di and D2 receptors. Although the differences in number and amplitude of jaw movements may have resulted from differences in the degree in which the dopaminergic postsynaptic activity is altered by YM-14673 and by direct receptor stimulation with SKF 82958 + quinpirole, the absence (YM-14673) or presence (SKF 82958 + quinpirole) of tongue protrusions cannot be ascribed to such differences. Secondly, it has reported that the effects of YM-14673 could be blocked only partially by a dose of the dopamine D1/D2 receptor antagonist cis-(Z)-flupentixol (1) that is highly effective in blocking the effects of dopamine receptor agonists upon jaw movements (15) . Together, these data strongly suggest that YM-14673 has distinct effects, apart from those that rely upon dopamine transmission.
Taking the above-mentioned findings and considerations together, it appears that the TRH-analogue YM-14673 can induce behavioural effects by the mechanisms which can directly and/or indirectly enhance the dopamine activity at the level of dopamine D1/D2 receptors in the shell and/or the core of the nucleus accumbens. Although such mechanisms may at least partly contribute to the ability of YM-14673 to elicit jaw movements after injections into the structures, it is evident that additional mechanisms must play a role in the display of jaw movements.
